Objective To discuss the clinical effect of Xipayinguyinye on oral bacteria in vitro and gingivitis in vivo.Methods Took the method of agar dilution to measure the minimum inhibitory concentration (MIC) of Xipayinguyinye on Porphyromonas gingivalis ( P.gingivalis),Prevotella intermedia ( P.intermedia ) and Fusobacterium nucleatum( F.nucleatum)in vitro;choose 112 patients with simple gingivitis and they were randomly divided into the research group and control group.The research group(56 cases)received the treatment of Xipayiguyinye,while the control group(56 cases)received the treatment without effect components.Both groups received 7 days of treatment and then observed the changes of sulcus bleeding index ( SBI ) and plaque index ( PLI ) before and after the treatment.Results MICof Xipayiguyinye in vitro was 1.0g/L for P.gingivalis and F.nucleatum and 0.5g/L for P.intermedia.There was no statistifically significant difference in SBI and PLI between two groups before the treatment(P ＞0.05) ;there was significant difference in SBI and PLI of research group before and after the treatment ( P ＜ 0.05 ) ; there was no significant difference in SBI and PLI of control group before and after the treatment( P ＞ 0.05 ) ;there was significant difference in SBI and PLI in SBI and PLI between two groups after the treatment ( P ＜ 0.05 ).Conclusion Xipayiguyinye could prevent bacteriostasis well and decrease the accumulation of dental plaque,reduce SBI and improve the health of the gingiva in vivo.

AIM: To investigate the relationship between genotypes of rs628031, rs650284, rs683369 of SLC22A1 gene and the toxicities and clinical response of oxaliplatin in patients with colorectal cancer. METHODS: A total of 72 patients diagnosed as colorectal cancer during January 2018 to June 2018 were selected and all patients received oxaliplatin treatment. Their peripheral venous blood was collected and genotyping was conducted by using SNaPshot. The toxicities including gastrointestinal toxicity, hematological toxicity and peripheral neurotoxicity were evaluated according to the Common Terminology Criteria Adverse Events (CTCAE) Version 5.0. Clinical response was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1). RESULTS: The results of Chi-test showed that different genotypes of SLC22A1 SNP sites rs628031 and rs683369 may be related to the toxicities and clinical response of oxaliplatin significantly. Specifically, when compared with the patients with GG type of rs628031, the patients with the GA or AA type had a lower incidence of grade 3 nausea and vomiting (P=0.017) and may also be less responsive to efficacy (P=0.008). When compared with the patients with CC type of rs683369, the patients with the GC or GG type had a lower incidence of grade 3 nausea and vomiting (P=0.002) and may also be less responsive to efficacy (P=0.014).CONCLUSION: The polymorphisms of SLC22A1 gene are closely related to the toxicities and clinical response of oxaliplatin in patients with colorectal cancer, which may be helpful for improving clinical treatment.